1. Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?
- Author
-
Brian B. Graham, Joan F. Hilton, Michael H. Lee, Rahul Kumar, Dara Fonseca Balladares, Farbod N. Rahaghi, Raúl San José Estépar, Claudia Mickael, Rodrigo Luís Barbosa Lima, Camila M.C. Loureiro, Juliana Lucena, Rudolf K.F. Oliveira, and Ricardo de Amorim Corrêa
- Subjects
pulmonary arterial hypertension ,schistosomiasis ,portal hypertension ,TGF-beta signaling ,thromboembolism ,Surgery ,RD1-811 ,Specialties of internal medicine ,RC581-951 - Abstract
Pulmonary arterial hypertension associated with schistosomiasis (SchPAH) and pulmonary arterial hypertension associated with portal hypertension (PoPAH) are lung diseases that develop in the presence of liver diseases. However, mechanistic pathways by which the underlying liver conditions and other drivers contribute to the development and progression of pulmonary arterial hypertension (PAH) are unclear for both etiologies. In turn, these unknowns limit certainty of strategies to prevent, diagnose, and reverse the resultant PAH. Here we consider specific mechanisms that contribute to SchPAH and PoPAH, identifying those that may be shared and those that appear to be unique to each etiology, in the hope that this exploration will both highlight known causal drivers and identify knowledge gaps appropriate for future research. Overall, the key pathophysiologic differences that we identify between SchPAH and PoPAH suggest that they are not variants of a single condition.
- Published
- 2023
- Full Text
- View/download PDF